Por Renan Filho · 2026-11-06
**Lead**
The United States Food and Drug Administration (FDA) has granted tentative approval for a cheap, generic version of lenacapavir, the revolutionary injectable drug shown to prevent HIV infection with just two doses per year. The decision, announced on Wednesday, marks a critical step in making the treatment accessible at a fraction of the current cost, with significant implications for the British public health system and global HIV prevention efforts.
**Contexto**
Lenacapavir, developed by Gilead Sciences under the brand name Sunlenca, was originally approved in the US as a treatment for multi-drug resistant HIV. However, landmark clinical trial data published in mid-2024 demonstrated that when used as pre-exposure prophylaxis (PrEP), a twice-yearly injection of lenacapavir reduced HIV acquisition risk by over 96 percent among cisgender women and provided superior protection compared to daily oral pills in men who have sex with men. The World Health Organization has since described lenacapavir as a potential “game changer” for HIV prevention, particularly in populations where adherence to daily oral PrEP remains a challenge.
The generic version approved this week was developed by the Medicines Patent Pool (MPP) and a consortium of Indian manufacturers, under a voluntary licensing agreement signed with Gilead in October 2024. That agreement allows 120 low- and middle-income countries to produce and distribute generic lenacapavir at cost. The UK is not among those countries, as it is classified as a high-income nation, but the FDA’s tentative approval signals that manufacturing capacity now exists to supply the drug at dramatically reduced prices — estimated to be as low as £100 per patient per year, compared to the current list price of more than £22,000 annually in the United States.
In the UK, lenacapavir is currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for HIV treatment, but it is not yet approved for PrEP. The National Institute for Health and Care Excellence (NICE) is expected to begin an appraisal for the preventive use of lenacapavir in early 2026. The FDA’s generic approval could accelerate those talks, as it provides concrete evidence that an affordable manufacturing supply chain is feasible.
**Analise**
The economic impact of this development cannot be overstated. The current annual cost of providing oral PrEP to one person in the UK is roughly £350 to £500, accounting for the drug itself, clinic visits, and monitoring. Injectable lenacapavir, even at a conservative NHS-negotiated price of £2,000 per patient per year, would still represent a significant saving in the long term if it prevents thousands of new infections and the associated lifetime treatment costs, which can exceed £360,000 per patient. The availability of a generic version at a fraction of the branded price could put pressure on both Gilead and the NHS to strike a much lower deal, or alternatively, could encourage the UK government to consider compulsory licensing mechanisms to access the generic supply directly — a move that British officials have not ruled out in past public health emergencies.
Moreover, the FDA’s tentative approval is a clear signal to global markets that the production of high-quality, affordable lenacapavir is no longer a theoretical exercise. The British pharmaceutical sector, which includes major manufacturing hubs in the north of England and Scotland, may also see opportunities to license the technology and produce the drug domestically, reducing reliance on overseas supply chains. However, the issue remains politically sensitive, as the UK’s trade agreements with the United States include provisions on intellectual property protection that could complicate any attempt to bypass Gilead’s patent directly.
Beyond the financial arithmetic, the approval carries profound public health implications. The UK recorded roughly 2,500 new HIV diagnoses in 2024, a figure that has plateaued in recent years after steady declines. Health officials have repeatedly stated that ending new HIV transmissions by 2030 — a government target — will require innovative prevention tools that reach populations often missed by daily pill regimens, including homeless individuals, migrants, and people struggling with substance use. A low-cost, twice-yearly injection could be a decisive tool in that effort, particularly if it is made available through sexual health clinics and community outreach programmes without significant out-of-pocket costs.
**Fontes**
This report is based on information released by the US Food and Drug Administration, the Medicines Patent Pool, Gilead Sciences, and the World Health Organization. Additional context was drawn from public statements by the UK Health Security Agency, the National Institute for Health and Care Excellence, and the British HIV Association. No interviews or exclusive FORTIS NEWS reporting were used in the preparation of this article.